Investor Presentaiton

Investor Presentation First six months of 2018 Slide 63 VictozaⓇ maintains a 14% value market share in the GLP-1, SGLT-2 and DPP-IV segment Segment value Share of segment value growth Segment value market shares DKK billion VictozaⓇ Other GLP-1 SGLT-2 DPP-IV 250 100% 100% 12% 13% 200 80% 80% CAGR¹ value: 25.7% 150 60% 60% 100 40% 40% VictozaⓇ: 14% 50 20% 20% 0% 0% May 2013 May 2018 2016 vs 2017 2017 vs 2018 May 2013 May 2018 1 CAGR for 5-year period Note: Segment only includes DPP-IV, GLP-1 & SGLT-2. Other oral anti-diabetic agents and insulin excluded Source: IQVIA MAT May, 2018 value figures changing diabetes® novo nordisk

View entire presentation